免疫系统
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
病毒学
2019年冠状病毒病(COVID-19)
阅读(过程)
2019-20冠状病毒爆发
医学
免疫学
生物
传染病(医学专业)
疾病
爆发
病理
哲学
语言学
作者
Haibo Li,Hongyu Liu,Hongping Wu,Chang Ming Guo,Wenting Zuo,Ying Zheng,Xiaoyan Deng,Jiuyang Xu,Yeming Wang,Zai Wang,Binghuai Lu,Baidong Hou,Bin Cao
标识
DOI:10.1080/22221751.2025.2494705
摘要
The dynamics of the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infections remain unclear, particularly when compared to responses in naive individuals. In this longitudinal prospective cohort study, 13 participants were recruited. Peripheral blood samples were collected every other day until day 7 after symptom onset. Transcriptome sequencing, single-cell sequencing, T-cell receptor (TCR) sequencing, B-cell receptor (BCR) sequencing, Olink proteomics, and antigen-antibody binding experiments were then performed. During the incubation periods of breakthrough infections, peripheral blood exhibited type 2 cytokine response, which shifted to type 1 cytokine response upon symptom onset. Plasma cytokine levels of C-X-C motif chemokine ligand 10, monocyte chemoattractant protein-1, interferon-γ, and interleukin-6 show larger changes in breakthrough infections than naïve infections. The inflammatory response in breakthrough infections rapidly subsided, returning to homeostasis by day 5 after symptom onset. Notably, the levels of monocyte-derived S100A8/A9, previously considered a marker of severe disease, physiologically significantly increased in the early stages of mild cases and persisted until day 7, suggesting a specific biological function. Longitudinal tracking also revealed that antibodies anti-Receptor Binding Domain (anti-RBD) in breakthrough infections significantly increased by day 7 after symptom onset, whereas cytotoxic T lymphocytes appeared by day 5. This study presents a reference for interpreting the immunological response to breakthrough infectious disease in humans.
科研通智能强力驱动
Strongly Powered by AbleSci AI